Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 20, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On April 19, 2007, the Administrators of the GlaxoSmithKline Annual Investment Plan notified the Company of an increase in share interests for specific individuals. These increases resulted from the re-investment of dividends paid to shareholders on April 12, 2007, at a price of GBP 14.66 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions.
Important Facts for Investors
- Dividend re-investment transactions occurred on April 19, 2007, at a price of GBP 14.66 per share.
- Notified individuals and their respective share increases include: Dr M M Slaoui (201), Mr R M Bondy (262), Mr M M Dunoyer (98), Mr D Learmouth (40), Dr D Pulman (148), and Mr A P Witty (91).
- The transactions were notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
- The report was signed by Victoria Whyte, Authorised Signatory, on April 20, 2007.